Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1998-07-13
1999-12-07
Lau, Kawai
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530324, 435 6, C07K 1447, C12Q 168, A61K 3817
Patent
active
05998371&
ABSTRACT:
The present invention provides a human selenoprotein (HSEL) and polynucleotides which identify and encode HSEL. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HSEL and a method for producing HSEL. The invention also provides for agonists, antibodies, or antagonists specifically binding HSEL, and their use, in the prevention and treatment of diseases associated with expression of HSEL. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HSEL for the treatment of diseases associated with the expression of HSEL. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HSEL.
REFERENCES:
Medina, D. et al., "Current ideas on selenium as a chemopreventive agent"Pathol, Immunopathos, Res., 7:187-199 (1988).
Morris, J.G. et al., "Selenium deficiency in cattle associated with Heinz bodies and anemia"Science, 223:491-493 (1984).
Batist, et al., "Cardiac and red blood cell glutathione peroxidase: results of a prospective randomized trial in patients on total parenteral nutrition"Cancer Res., 45:5900-5903 (1985).
Ip, C. "The chemopreventive role of selenium in carcinogenesis"Adv. Exp. Med. Bio., 206:431-447 (1986).
Holmberg, S.B. et al., "Chemoprevention of cancer. Epidemiology and basic research point to new directions"Nord. Med., 106:86-89 (1991). (Non-English article with abstract in English).
Vendeland, S.C. et al., "Rat skeletal muscle selenoprotein W:cDNA clone and mRNA modulation by dietary selenium"Proc. Natl. Acad. Sci. USA, 92:8749-8753 (1995).
Zachara, B.A. "Mammalian selenoproteins"J. Trace Elem. Electrolytes Health Dis., 6:137-151 (1992).
Mandel, S. J. et al., "Cloning and in vitro expression of the human selenoproteins, type I iodothyronine deiodinase"J.Clin. Endocrinol. Metab., 75:1133-1139 (1992).
Gladyshev, V.N. et al., "Selenocysteine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene"Proc. Natl. Acad.Sci.USA, 93:6146-6151 (1996).
Zhu, A. et al., "Effect of selenium on malignant tumor cells of brain"Biol.Trace Elem.Res., 49:1-7 (1995).
Morrison, D.G. et al., "Intracellular 58-kd selenoprotein level correlate with inhibition of DNA synthesis in mammary epithelial cells"Carcinogenesis, 9:1801-1810 (1988).
Gerogiou, G., "Optimizing the Production of Recombinant Proteins in Microorganims", AlChE J., 92:8749-8753 (1995).
Vendeland, S.C. et al., (Direct Submission), GenBank Sequence Database (Accession U25264), National Center for Biotechnology Information, National Library of Medicine, Bethesda, Maryland, 20894, (GI 984811).
Database EST-STS, Accession number H61256, Hillier et al., The Washington University-Merck EST Project, Oct. 6, 1995.
Goli Surya K.
Hillman Jennifer L.
Incyte Pharmaceuticals Inc.
Lau Kawai
LandOfFree
Human selenoprotein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human selenoprotein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human selenoprotein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-823783